CYP4F11 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4269299	1.00	2/20
SCHEMBL4269302	1.00	2/20
SCHEMBL5970916	0.55	2/20
SCHEMBL5665730	0.41	2/20
SCHEMBL5665735	0.41	2/20
SCHEMBL13060909	0.40	2/20
SCHEMBL14264483	0.40	2/20
SCHEMBL5679276	0.39	2/20
SCHEMBL5679282	0.39	2/20
SCHEMBL16798246	0.37	2/20
SCHEMBL18012065	0.36	2/20
SCHEMBL18430941	0.36	2/20
SCHEMBL16079472	0.64	1/20
SCHEMBL11158755	0.62	1/20
SCHEMBL765000	0.61	1/20
SCHEMBL765847	0.61	1/20
SCHEMBL10289874	0.61	1/20
SCHEMBL7808534	0.60	1/20
SCHEMBL5050631	0.59	1/20
SCHEMBL5545806	0.59	1/20

Clinical trials — most relevant to CYP4F11 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity	PHASE4	COMPLETED
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies	PHASE4	RECRUITING
OPTImization of the Dose of tacroliMUS by Bayesian Prediction	PHASE4	COMPLETED
Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)	PHASE3	COMPLETED
Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer	PHASE1/PHASE2	COMPLETED
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer	PHASE2	RECRUITING
Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities	PHASE2	UNKNOWN
Asciminib in HER2+ Breast Cancer Brain Metastases	PHASE1/PHASE2	NOT_YET_RECRUITING
Effect of Dexamethasone on CYP Enzyme Activity in Healthy Male Subjects	PHASE1	NOT_YET_RECRUITING
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer	PHASE1	RECRUITING
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors	PHASE1	UNKNOWN
Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot	PHASE1	COMPLETED
A Phase I Trial of QLS1410 in Healthy Chinese Adults and Participants With Mild Essential Hypertension	PHASE1	NOT_YET_RECRUITING
The Study of Warfarin Maintenance Dose in Chinese Patients	nan	UNKNOWN
The Clinical and Economic Impact of Pharmacogenomic Testing for Tamoxifen Metabolism in Postmenopausal Women Receiving Tamoxifen for Prevention of Recurrent Breast Cancer	nan	COMPLETED
Pharmacogenetic Dosage Algorithm for Acenocoumarol	nan	COMPLETED
Connecting Breath and Mind for CYP With Long COVID	nan	UNKNOWN
Cholesterol and CYP3A4/5 Metabolism Across Pregnancy and Postpartum	nan	COMPLETED
A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment	nan	UNKNOWN
Influence of a Combined Pharmacogenetic Score on Through Plasma Voriconazole Concentrations in Haematological Patients	nan	COMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Effects of Genotype on CYP2C9 Drug Interactions	nan	COMPLETED
Cholesterol Metabolites as Markers for CYP3A Induction	nan	COMPLETED
Cyclophosphamide in Lupus Nephritis	nan	UNKNOWN
Aromatase Inhibitor Clinical Trial	nan	UNKNOWN
PhaRmacOgenetics and Therapeutic Drug Monitoring In SchizophrEnia	nan	NOT_YET_RECRUITING
A Pilot Study of Varying Doses of Tamoxifen in the Setting of Genetic Polymorphisms of CYP2D6	nan	COMPLETED
Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline	nan	COMPLETED
Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CYP4F11 binder may also engage these)

Protein	Name	Similarity
CYP4F3	Cytochrome P450 4F3	1.000	landscape →
CYP4F2	Cytochrome P450 4F2	1.000	landscape →
P51869	—	0.997	P51869 →
CYP4Z1	Cytochrome P450 4Z1	0.995	landscape →
Q9EP75	—	0.993	Q9EP75 →
Q6ZWL3	—	0.992	Q6ZWL3 →
Q6NT55	—	0.990	Q6NT55 →
P51871	—	0.990	P51871 →
P51870	—	0.990	P51870 →
Q6A152	—	0.989	Q6A152 →
P33274	—	0.989	P33274 →
P24456	—	0.989	P24456 →
P15129	—	0.989	P15129 →
P15128	—	0.988	P15128 →
P20816	—	0.988	P20816 →
Q64462	—	0.988	Q64462 →
Q8K4D6	—	0.988	Q8K4D6 →
CYP4X1	Cytochrome P450 4X1	0.988	landscape →
CYP4F8	Cytochrome P450 4F8	0.987	landscape →
P08516	—	0.987	P08516 →
Q3MID2	—	0.987	Q3MID2 →
CYP4F12	Cytochrome P450 4F12	0.987	landscape →
Q9GLL1	—	0.987	Q9GLL1 →
Q99N16	—	0.986	Q99N16 →
CYP21A2	Steroid 21-hydroxylase	0.985	landscape →
Q64680	—	0.985	Q64680 →
Q5RCN6	—	0.985	Q5RCN6 →
P11714	—	0.984	P11714 →
Q64403	—	0.983	Q64403 →
P12938	—	0.982	P12938 →